Obicetrapib/Ezetimibe(Obicetrapib/Ezetimibe) - 药物靶点：CETP x NPC1L1_在研适应症：动脉粥样硬化斑块_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

CETP x NPC1L1

作用机制

CETP抑制剂(胆固醇转运蛋白抑制剂)、NPC1L1抑制剂(尼曼-匹克C1型类似蛋白-1抑制剂)

治疗领域

其他疾病

在研适应症

动脉粥样硬化斑块

非在研适应症-

原研机构

NewAmsterdam Pharma Co. NV

在研机构

NewAmsterdam Pharma Holding BV

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C32H31F9N4O5

InChIKeyNRWORBQAOQVYBJ-GJZUVCINSA-N

CAS号866399-87-3

查看全部结构式(2)

关联

2

项与 Obicetrapib/Ezetimibe 相关的临床试验

NCT06005597 / Active, not recruiting临床3期

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk Factors

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.

开始日期2024-03-01

申办/合作机构

NewAmsterdam Pharma Co. NV

NCT06305559 / Not yet recruiting临床3期

A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial)

This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).

开始日期2024-03-01

申办/合作机构

NewAmsterdam Pharma Holding BV

100 项与 Obicetrapib/Ezetimibe 相关的临床结果

登录后查看更多信息

100 项与 Obicetrapib/Ezetimibe 相关的转化医学

登录后查看更多信息

100 项与 Obicetrapib/Ezetimibe 相关的专利（医药）

登录后查看更多信息

100 项与 Obicetrapib/Ezetimibe 相关的药物交易

登录后查看更多信息